Front Immunol
PLoS One
Immunology
Smash technology
Smash technology
Humanized PD-1/PD-L1 mouse and cell line
An inducible Knockdown cell line defines a model in which a specific target of interest can be shut down upon treatment.
We use SMASh technology to generate drug inducible protein degradation models. Through a single genetic modification, the addition of a self-cleaving degron tag to a protein of interest allows its inducible, and reversible, degradation upon treatment (further reading).
genOway has an exclusive license for the use of the patented SMASh technology. (See press release)
→ Risks can be strongly minimized by applying in-depth bio-informatic, genetic, and bibliographic analyses
→ An alternative model is a functional Knockout by introducing a point mutation to produce an inactive protein
Immune checkpoint PD-L1 has been identified as a therapeutic target in immuno-oncology and different treatments have been successfully developed to target this protein in oncology.
We developed mouse tumor MC38 cells invalidated for mouse Pd-l1 and overexpressing a SMASh-tagged form of human PD-L1 to reversibly shut down its expression in these cells, thus obtaining cells entirely devoid of PD-L1 upon drug treatment.
Two cell lines developed:
For academic research:
For bio-pharmaceutical research & development:
Human PD-L1 expression was analyzed by flow cytometry. MC38 parental line was used as a negative control. Human colon carcinoma cell line RKO was used as a positive control. Both tagged cell lines express detectable levels of human PD-L1. Note that the position of the SMASh-tag can impact the targeted protein’s level of expression, as MC38-hPD-L1-SMASh cells express higher levels of human PD-L1 than MC38-SMASh-hPD-L1.
Front Immunol
PLoS One
Immunology
Smash technology
Smash technology
Humanized PD-1/PD-L1 mouse and cell line
Let us know how we can help